SeaBeLife Biotech

SeaBeLife is a biotechnology startup based in Brittany, France, founded in 2019. The company focuses on developing innovative drug candidates to address severe pathologies, particularly acute liver and kidney diseases, for which effective treatments are currently lacking. SeaBeLife's research also extends to degenerative and ocular conditions, including Parkinson's disease and AMD. Led by CEO Morgane Rousselot and built on the research of Stéphane Bach, Marie-Thérèse Dimanche-Boitrel, and Claire Delehouzé, SeaBeLife has gained attention in the investment community. The startup recently secured a €1.20M Seed Round investment on 26 September 2023. The investment came from notable venture capital firms including Angels Santé, iXLife Capital, WeLike, BADGE Business Angels des Grandes Ecoles, and BREIZH Angels. SeaBeLife's promising portfolio of over 45 biologically-active molecules and the filing of four patents further solidify the company's position in the biotech space. With its groundbreaking research and strong investor backing, SeaBeLife is poised to make significant advancements in addressing critical medical needs and carving a prominent place in the biotechnology industry.